Bristol Myers Squibb (NYSE: BMY) has announced the European Commission's (EC) expanded approval of Reblozyl® (luspatercept) for the first-line ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
Voydeya (danicopan) has been granted approval in the United States as an add-on therapy for the treatment of extravascular haemolysis (EVH) in adults diagn...
LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, a...
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...
— If approved, would confirm 2021 conditional approval and expand indication to more patients — HUTCHMED (China) Lim...
cTTP, an ultra-rare blood clotting disorder, presents life-threatening acute events and debilitating chronic symptoms. Untreated acute TTP ...
Johnson & Johnson has announced the approval of OPSYNVI® by the U.S. Food and Drug Administration (FDA), marking a significant advanc...
“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bemped...
• The agreement furthers Hovione´s ability to bring the benefits of continuous tableting, including reduced time to market and in...
Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy conditions, has achieved a significant milestone ...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
The newly granted patent enriches Salipro Biotech's comprehensive intellectual property (IP) portfolio, securing its method for stabilizing challenging dru...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...
© 2025 Biopharma Boardroom. All Rights Reserved.
